Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Working towards a cure in CML

Jorge Cortes • 4 Jun 2022
ASCO 2022
Chronic Myeloid Leukemia Leukemia Venetoclax

Jorge Cortes, MD, Georgia Cancer Center, Augusta, GA, reflects on the potential for a cure in patients with chronic myeloid leukemia (CML), highlighting treatment discontinuation in 20-25% of patients treated with a tyrosine kinase inhibitor (TKI). Future endeavors are focusing on increasing the percentage of patients with CML achieving prolonged remission. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Jorge Cortes

2:12
Key emerging trials in CML and the importance of improving treatment-free remission rates
Jorge Cortes • 7 Sep 2023
2:09
Social determinants of health & their impact on patients with hematological malignancies
Jorge Cortes • 7 Sep 2023
1:57
Post-hoc analysis of OPTIC: patient responses to ponatinib by T315I mutational status
Jorge Cortes • 7 Sep 2023
2:21
Exciting updates in the field of CML: disease pathophysiology & novel agents
Jorge Cortes • 7 Sep 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals